



COVID-19 and Mpox

Situational Report in the ASEAN Region

—— ASEAN BioDiaspora Virtual Center (ABVC)



ASSOCIATION OF SOUTHEAST ASIAN NATIONS



ASEAN BIODIASPORA VIRTUAL CENTER (ABVC)



MINISTRY OF HEALTH
REPUBLIC OF INDONESIA

GLOBAL PARTNERS



In partnership with
Canada



**World Health
Organization**



Korea Disease Control and
Prevention Agency



Table of Contents

COVID-19	1
Highlights and Situation Overview	1
Global Update	1
Regional Update	1
Research Update	2
COVID-19 Cases and Deaths Table	3
COVID-19 Cases in ASEAN Region Table	3
Epi curve Among ASEAN Countries	4
ASEAN Weekly New Cases and New Deaths	5
Vaccination Status in ASEAN	6
Mpox	7
Map of Mpox Cases Globally	7
Mpox Daily Trend Globally	8
Highlights and Situation Overview	9
Mpox Cases in ASEAN Region Table	9
Mpox Cases in Asia-Pacific Region Table	9
Top 5 Countries with Most Mpox Cases Globally	9
Mpox Cases per Region	10
References	11



COVID-19: Highlights and Situation Overview

Global Update

- **Worldwide**, there have been over 684 million cases and over 6 million deaths attributed to COVID-19.
- The **World Health Organization (WHO)** official said at a press briefing that though COVID-19 patterns are hard to predict, the XBB.1.16 Omicron subvariant is the one to watch and is fueling a steady rise in cases in India. In its weekly update on COVID-19 pandemic, the WHO said it added XBB.1.16 as the sixth variant under monitoring on March 22. It also said though global cases and deaths continue to decline, some countries including India are reporting recent spikes in cases. India this week reported its highest levels COVID-19 cases in 6 months, prompting stepped up testing and an advisory to increase mask use in New Delhi. In the Eastern Mediterranean region, Iran, Kuwait, and Libya reported the biggest proportional increases over the last 28 days, with the highest numbers reported from Iran, the United Arab Emirates, and Qatar. In the South East Asia region, India has both the highest proportional rise in cases and the most cases over the past 4 weeks while Indonesia reported a modest rise in cases. [\[Full report\]](#)
- The **U.S. Centers for Disease Control and Prevention (CDC)** said in its biweekly data summary that U.S. COVID-19 markers continue to decline in the country.¹ The 7-day average for new daily COVID cases is about 20,000, down by 9.2% compared to the previous 7-day average.¹ Furthermore, about 228 people die from COVID-19 each day, down by 29.4% compared to the previous 7-day average for deaths. In its latest variant proportion estimates, the CDC said XBB.1.5 has reached saturation, making up 87.9% of samples, and that three other Omicron subvariants including XBB.1.9.1, XBB, and XBB.1.5.1 show positive growth.¹ [\[Full report\]](#)
- **Iran's** Health Ministry categorizes 19 cities as 'red' or 'high risk' as the number of patients diagnosed with COVID-19 continues to surge countrywide.² The number of red cities rose from 10 to 19, while 45 cities were classified as 'orange' or 'moderate risk', which also increased from 194 to 233.² Iran confirmed 634 new cases of COVID-19 on April 2 (Sunday) as well as 22 deaths.² The health ministry advised those who are infected should stay at home for at least five days from the onset of their symptoms.² It also encouraged the public to take booster doses to curb further spread of COVID-19.² [\[Full article\]](#)
- **India** has recorded a sharp jump in daily COVID-19 cases.³ According to the health ministry data released on April 3 (Monday), the country reported 1,830 new COVID-19 cases in the past 24 hours, bringing the country's active caseload to 21,219.³ In the week of March 26 to April 1, India recorded over 18,450 COVID-19 cases, more than double of the weekly cases in the previous week.³ [\[Full article\]](#)

Regional Update

- **Indonesia:** The government has chosen to extend the COVID-19 pandemic's health emergency designation until at least May 2023.⁵ Muhadjir Effendy, Coordinating Human Development and Culture Minister, made the announcement on April 3 during a coordination meeting attended by Health Minister Budi Gunadi Sadikin, Agriculture Minister Syahrul Yasin Limpo, and Suharyanto, head of the National Disaster Mitigation Agency (BNPB).⁵ [\[Full article\]](#)
- **Myanmar** has extended COVID-19 preventive measures till April 30, according to authorities.⁶ The extension applies to all COVID-19 limitations that expire on March 31, except those that will be lifted, according to the Central Committee on Prevention,



Control, and Treatment, says Xinhua.⁶ It went on to say that the extension applies to all previous orders, announcements, and instructions issued by different government organizations and ministries in order to combat the pandemic.⁶

- **Philippines:** The daily average of new coronavirus disease 2019 (COVID-19) cases in the Philippines increased by 33% from March 27 to April 2, according to the Department of Health (DOH) on April 3.⁷ [\[Full article\]](#)

Research Update (Published and peer-reviewed studies)

- Determining the lowest effective dose of anticoagulation therapy for patients with hypoxemic COVID-19 pneumonia is imperative.⁴ This paper, ***Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia The ANTICOVID Randomized Clinical Trial***, compares the clinical outcomes among the 3 strategies: therapeutic anticoagulation (TA), high-dose prophylactic anticoagulation (HD-PA) and standard-dose prophylactic anticoagulation (SD-PA).⁴ The ANTICOVID randomized clinical open-label trial included patients with hypoxemic COVID-19 pneumonia requiring supplemental oxygen and having no initial thrombosis on chest computer tomography with pulmonary angiogram at 23 health centers in France from April 14 to December 13, 2021.⁴ Of 339 patients randomized, 334 were included in the primary analysis—114 patients in the SD-PA group, 110 in the HD-PA, and 110 in the TA.⁴ At randomization, 90% of the patients were in the intensive care unit.⁴ Data analyses were performed from April 13, 2022, to January 3, 2023.⁴ Patients were randomly assigned (1:1:1) to receive either SD-PA, HD-PA, or TA with low-molecular-weight or unfractionated heparin for 14 days.⁴ A hierarchical criterion of all-cause mortality followed by time to clinical improvement at day 28 was the main outcome.⁴ Main secondary outcome was net clinical outcome at day 28 (composite of thrombosis, major bleeding, and all-cause death).⁴ Among the study population of 334 individuals (mean age, 58.3 years; 226 men and 108 women), use of HD-PA and SD-PA had similar probabilities of favorable outcome (47.3% [95% CI, 39.9% to 54.8%] vs 52.7% [95% CI, 45.2% to 60.1%]; $P = .48$), as did TA compared with SD-PA (50.9% [95% CI, 43.4% to 58.3%] vs 49.1% [95% CI, 41.7% to 56.6%]; $P = .82$) and TA compared with HD-PA (53.5% [95% CI 45.8% to 60.9%] vs 46.5% [95% CI, 39.1% to 54.2%]; $P = .37$).⁴ Net clinical outcome was met in 29.8% of patients receiving SD-PA (20.2% thrombosis, 2.6% bleeding, 14.0% death), 16.4% receiving HD-PA (5.5% thrombosis, 3.6% bleeding, 11.8% death), and 20.0% receiving TA (5.5% thrombosis, 3.6% bleeding, 12.7% death).⁴ Moreover, use of HD-PA and TA significantly reduced thrombosis compared with SD-PA (absolute difference, -14.7 [95% CI -6.2 to -23.2] and -14.7 [95% CI -6.2 to -23.2], respectively).⁴ Use of HD-PA significantly reduced net clinical outcome compared with SD-PA (absolute difference, -13.5 ; 95% CI -2.6 to -24.3).⁴ This randomized clinical trial found that compared with SD-PA, neither HD-PA nor TA use improved the primary hierarchical outcome of all-cause mortality or time to clinical improvement in patients with hypoxemic COVID-19 pneumonia; however, HD-PA resulted in significantly better net clinical outcome by decreasing the risk of de novo thrombosis.⁴ [\[Full text\]](#)



Cases and Deaths as of 03 April 2023

- As of 03 April 2023 (1PM, GMT+7), worldwide, there were **684,070,904** confirmed cases, including **6,832,234** deaths. Globally, Case Fatality Rate (CFR) was **1.0%**.
- 35,664,515 confirmed cases** of COVID-19 have been reported in the **ASEAN Region**.
- The Case Fatality Rate in the **ASEAN** Region is range between **0.1 to 3.1%**

COVID-19 cases in ASEAN region

REGION	COUNTRY	FIRST CONFIRMED CASE(S)	LATEST REPORT ON CONFIRMED CASE(S)	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS	CUMULATIVE CASES/ 100,000	CUMULATIVE VACCINATED	CUMULATIVE FULLY VACCINATED	CUMULATIVE BOOSTERED	FULLY VACCINATED/ 100
ASEAN REGION	Brunei Darussalam	10 Mar 20	30-Mar-23	283,345	-	225	-	64,053	450,404	445,929	338,987	99.3
	Cambodia	27 Jan 20	28-Mar-23	138,725	-	3,056	-	841	15,244,858	14,609,937	10,433,215	87.1
	Indonesia	02 Mar 20	03-Apr-23	6,747,474	111	161,027	-	2,490	203,657,535	172,693,321	67,952,274	62.7
	Lao PDR	24 Mar 20	01-Apr-23	218,037	-	758	-	3,041	5,888,649	5,222,417		69.4
	Malaysia	25 Jan 20	28-Mar-23	5,049,268	-	36,979	-	15,788	28,125,245	27,536,657	17,056,957	81.1
	Myanmar	23 Mar 20	29-Mar-23	634,078	-	19,490	-	1,173	34,777,314	27,545,329	2,227,351	50.8
	Philippines	30 Jan 20	02-Apr-23	4,081,818	-	66,390	-	3,771	78,369,243	73,937,435	21,341,197	64.0
	Singapore	23 Jan 20	17-Mar-23	2,255,812	-	1,722	-	39,049	5,161,990	5,120,768	4,440,289	90.8
	Thailand	13 Jan 20	27-Mar-23	4,728,632	-	33,935	-	6,791	57,005,497	53,486,086	32,143,431	74.6
	Vietnam	23 Jan 20	02-Apr-23	11,527,326	10	43,186	-	11,950	90,450,881	85,848,363	57,452,750	87.4
ASEAN COUNTRIES				35,664,515	121	366,768	-	148,946	519,131,616	466,446,242	213,386,451	


*There have been no tests reported in the last 14 days in the **ASEAN** Region.

REGION	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS
ASIA	193,636,288	4,477	1,200,783	7
AFRICA	12,810,730	-	258,663	
AMERICAS	194,051,230	-	2,975,027	
EUROPE	247,908,141	-	2,030,993	-
TOTAL	648,406,389	4,477	6,465,466	7



COVID-19 Epi curve among ASEAN Countries:

From January 1, 2022 to April 3, 2023




Cumulative cases of COVID-19 in the ASEAN Region as of April 3, 2023 (Report generated by ASEAN Biodiaspora Virtual Center)

*Data from Bluedot Insights, cases may differ from how data is reported in countries and other authorities. Data may be subject to retrospective correction by national authorities.



ASEAN Weekly COVID-19 New Cases and New Deaths


From January 1, 2022 to April 2, 2023





ASEAN COVID-19 Vaccination Status

as of 09 March 2023




*Last update in COVID-19 vaccination status in ASEAN was on March 9, 2023.





Mpox (Monkeypox) Cases Reported Globally


as of March 31, 2023





Mpox Daily Trend Globally

as of March 31, 2023





Mpox: Highlights and Situation Overview

- As of 31 March 2023 (1PM, GMT+7), worldwide, there were **86,791** confirmed cases, including **112** deaths. Globally, Case Fatality Rate (CFR) was **0.13%**.
- 47 confirmed cases** in the ASEAN region, with CFR of **0%**.
- 86,744 confirmed cases** of Mpox have been reported in other **5 regions** (other than ASEAN region):

Mpox cases in ASEAN region

Country	Total Cases	New Cases	Deaths	Case Fatality Rate (CFR)
Indonesia	1	-	-	0.00%
Philippines	4	-	-	0.00%
Singapore	22	1	-	0.00%
Thailand	18	-	-	0.00%
Vietnam	2	-	-	0.00%
ASEAN Total	47	1	-	0.00%

Mpox cases in Asia-Pacific region

Country/Territory	Total Cases	New Cases	Deaths	Case Fatality Rate (CFR)
Australia	144	-	-	0.00%
India	22	-	1	5.00%
Japan	82	2	-	0.00%
New Caledonia	1	-	-	0.00%
New Zealand	41	-	-	0.00%
People's Republic of China*	24	-	-	0.00%
Republic of Korea*	5	-	-	0.00%
Sri Lanka	2	-	-	0.00%
Asia-Pacific Total	321	7	1	0.31%

*People's Republic of China – including Hong Kong (SAR), Macao (SAR), and Taiwan (Province of China)

Top 5 countries with most mpox cases globally

Country	Total Cases	New Cases	Deaths	Case Fatality Rate (CFR)
United States of America	30,079	4	38	0.13%
Brazil	10,890	-	15	0.14%
Spain	7,546	-	3	0.04%
France	4,128	-	-	0.00%
Colombia	4,089	-	-	0.00%



Mpox cases per region

REGION	TOTAL CONFIRMED CASES SINCE JANUARY 1, 2022	NEW CASES SINCE THE PREVIOUS REPORT	TOTAL DEATHS	CASE FATALITY RATE
AFRICA	1,494	7	19	1.27%
AMERICAS	59,026	16	86	0.15%
ASEAN	47	1	-	0.00%
ASIA PACIFIC	321	7	1	0.31%
EUROPE	25,582	1	6	0.02%
MIDDLE EAST	321	-	-	0.00%
TOTAL	86,791	32	112	0.13%



References

1. "Covid Data Tracker Weekly Review." *Centers for Disease Control and Prevention*, Centers for Disease Control and Prevention, 31 Mar. 2023, <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html>.
2. "'Red' Alert in 19 Cities on Iran's Coronavirus Map as More People Contract Covid-19." *Iran Front Page*, 1 Apr. 2023, <https://ifpnews.com/red-alert-in-19-cities-on-irans-coronavirus-map-as-more-people-contract-covid-19/>.
3. "Covid-19 in India Live Updates: Nashik Reports 33 New Cases in 24 Hours." *cnbctv18.Com*, 3 Apr. 2023, <https://www.cnbctv18.com/healthcare/covid19-live-updates-latest-news-coronavirus-india-cases-deaths-delhi-health-ministry-16321651.htm>.
4. Labbé, Vincent, et al. "Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients with Hypoxemic COVID-19 Pneumonia." *JAMA Internal Medicine*, 22 Mar. 2023, <https://doi.org/10.1001/jamainternmed.2023.0456>.
5. "Government Keeps COVID-19 Emergency Status until May." *The Jakarta Post*, 3 Apr. 2023, <https://www.thejakartapost.com/indonesia/2023/04/03/government-keeps-covid-19-emergency-status-until-may.html>.
6. "Myanmar Extends Covid Restrictions until April 30." *The Sentinel Assam*, The Sentinel Assam, 2 Apr. 2023, <https://www.sentinelassam.com/international/myanmar-extends-covid-restrictions-until-april-30-643658>.
7. Montemayor, Ma. Teresa. "Daily Average of PH Covid-19 Cases up by 33%." *Philippine News Agency*, 3 Apr. 2023, <https://www.pna.gov.ph/articles/1198828>.



Report generated by
ASEAN Biodiversity Virtual Center (ABVC)
in collaboration with **Bluedot Inc.**
Email: support@biodiaspora.org
Facebook: <https://facebook.com/ASEANBiodiaspora>
Instagram: <https://instagram.com/ASEANBiodiaspora>



In partnership with
Canada